227 related articles for article (PubMed ID: 22111588)
61. MicroRNA-139 suppresses proliferation in luminal type breast cancer cells by targeting Topoisomerase II alpha.
Hua W; Sa KD; Zhang X; Jia LT; Zhao J; Yang AG; Zhang R; Fan J; Bian K
Biochem Biophys Res Commun; 2015 Aug; 463(4):1077-83. PubMed ID: 26079880
[TBL] [Abstract][Full Text] [Related]
62. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y
Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769
[TBL] [Abstract][Full Text] [Related]
63. Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer.
Nygård SB; Christensen IJ; Smith DH; Nielsen SL; Jensen NF; Nielsen HJ; Vainer B; Brünner N
Scand J Gastroenterol; 2013 Dec; 48(12):1436-43. PubMed ID: 24138107
[TBL] [Abstract][Full Text] [Related]
64. A parental requirement for dual-specificity phosphatase 6 in zebrafish.
Maurer JM; Sagerström CG
BMC Dev Biol; 2018 Mar; 18(1):6. PubMed ID: 29544468
[TBL] [Abstract][Full Text] [Related]
65. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
Erriquez J; Becco P; Olivero M; Ponzone R; Maggiorotto F; Ferrero A; Scalzo MS; Canuto EM; Sapino A; Verdun di Cantogno L; Bruna P; Aglietta M; Di Renzo MF; Valabrega G
Gynecol Oncol; 2015 Sep; 138(3):627-33. PubMed ID: 26100858
[TBL] [Abstract][Full Text] [Related]
66. Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy.
Nikolényi A; Uhercsák G; Csenki M; Hamar S; Csörgo E; Tánczos E; Thurzó L; Brodowicz T; Wagnerova M; Kahán Z
Pathol Oncol Res; 2012 Jan; 18(1):61-8. PubMed ID: 21681601
[TBL] [Abstract][Full Text] [Related]
67. Igf2bp3 maintains maternal RNA stability and ensures early embryo development in zebrafish.
Ren F; Lin Q; Gong G; Du X; Dan H; Qin W; Miao R; Xiong Y; Xiao R; Li X; Gui JF; Mei J
Commun Biol; 2020 Mar; 3(1):94. PubMed ID: 32127635
[TBL] [Abstract][Full Text] [Related]
68. Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer.
Zheng H; Li X; Chen C; Chen J; Sun J; Sun S; Jin L; Li J; Sun S; Wu X
Int J Nanomedicine; 2016; 11():5519-5529. PubMed ID: 27799773
[TBL] [Abstract][Full Text] [Related]
69. Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase IIalpha genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization.
Murthy SK; Magliocco AM; Demetrick DJ
Arch Pathol Lab Med; 2005 Jan; 129(1):39-46. PubMed ID: 15628907
[TBL] [Abstract][Full Text] [Related]
70. Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer.
Zaczek A; Markiewicz A; Supernat A; Bednarz-Knoll N; Brandt B; Seroczyńska B; Skokowski J; Szade J; Czapiewski P; Biernat W; Wełnicka-Jaśkiewicz M; Jassem J
Pathol Oncol Res; 2012 Oct; 18(4):885-94. PubMed ID: 22426810
[TBL] [Abstract][Full Text] [Related]
71. A truncated cytoplasmic topoisomerase IIalpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34.
Mirski SE; Sparks KE; Yu Q; Lang AJ; Jain N; Campling BG; Cole SP
Int J Cancer; 2000 Feb; 85(4):534-9. PubMed ID: 10699927
[TBL] [Abstract][Full Text] [Related]
72. Evolutionary History of TOPIIA Topoisomerases in Animals.
Moreira F; Arenas M; Videira A; Pereira F
J Mol Evol; 2022 Apr; 90(2):149-165. PubMed ID: 35165762
[TBL] [Abstract][Full Text] [Related]
73. Brd4 and P300 Confer Transcriptional Competency during Zygotic Genome Activation.
Chan SH; Tang Y; Miao L; Darwich-Codore H; Vejnar CE; Beaudoin JD; Musaev D; Fernandez JP; Benitez MDJ; Bazzini AA; Moreno-Mateos MA; Giraldez AJ
Dev Cell; 2019 Jun; 49(6):867-881.e8. PubMed ID: 31211993
[TBL] [Abstract][Full Text] [Related]
74. Sister chromatid decatenation: bridging the gaps in our knowledge.
Broderick R; Niedzwiedz W
Cell Cycle; 2015; 14(19):3040-4. PubMed ID: 26266709
[TBL] [Abstract][Full Text] [Related]
75. Ythdf m
Kontur C; Jeong M; Cifuentes D; Giraldez AJ
Cell Rep; 2020 Dec; 33(13):108598. PubMed ID: 33378672
[TBL] [Abstract][Full Text] [Related]
76. Association of Topoisomerase II (TOP2A) and Dual-Specificity Phosphatase 6 (DUSP6) Single Nucleotide Polymorphisms with Radiation Treatment Response and Prognosis of Lung Cancer in Han Chinese.
Wang TL; Ren YW; Wang HT; Yu H; Zhao YX
Med Sci Monit; 2017 Feb; 23():984-993. PubMed ID: 28231233
[TBL] [Abstract][Full Text] [Related]
77. Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.
Atwal M; Lishman EL; Austin CA; Cowell IG
Mol Pharmacol; 2017 Jan; 91(1):49-57. PubMed ID: 27974636
[TBL] [Abstract][Full Text] [Related]
78. TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer.
Glynn RW; Mahon S; Curran C; Callagy G; Miller N; Kerin MJ
Oncologist; 2011; 16(7):949-55. PubMed ID: 21705665
[TBL] [Abstract][Full Text] [Related]
79. A chromatin remodeling complex regulates topoisomerase IIα function.
Cancer Discov; 2013 Jul; 3(7):OF33. PubMed ID: 23847378
[TBL] [Abstract][Full Text] [Related]
80. Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.
Betof AS; Rabbani ZN; Hardee ME; Kim SJ; Broadwater G; Bentley RC; Snyder SA; Vujaskovic Z; Oosterwijk E; Harris LN; Horton JK; Dewhirst MW; Blackwell KL
Br J Cancer; 2012 Feb; 106(5):916-22. PubMed ID: 22333602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
